odm-204
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02344017)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorINHIBITOR
AR inhibitor
- Cytochrome P450 17A1INHIBITOR
CYP17A1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(c1ccc(C#N)c(C(F)(F)F)c1)[C@@H]1C=C(n2ccnc2)CCC1(C)C- Mol. weight
- 374.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068517 ↗
Also known as
- odm-204
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02344017 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2015 | Institut Gustave Roussy, Orion Corporation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institut Gustave Roussy | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Orion Corporation | For profit | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1